• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Pelthos Therapeutics Inc.

    8/13/25 6:24:31 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTHS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Pelthos Therapeutics Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    171126204

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    171126204


    1Names of Reporting Persons

    AME Equities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORTH CAROLINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  This constitutes an exit filing for the reporting person.


    SCHEDULE 13G

    CUSIP No.
    171126204


    1Names of Reporting Persons

    Ruth Friedman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  This constitutes an exit filing for the reporting person.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Pelthos Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703
    Item 2. 
    (a)Name of person filing:

    (i) AME Equities LLC, a North Carolina limited liability company ("AME"); and (ii) Ruth Friedman ("Ms. Friedman"). The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons". Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to the Statement on Schedule 13G filed by the Reporting Persons with the U.S. Securities and Exchange Commission (the "SEC") on March 1, 2024 (the "Schedule 13G"), pursuant to which such Reporting Persons have agreed to file the Schedule 13G, this Amendment No. 1 to Schedule 13G (the "Amendment") and all subsequent amendments to the Schedule 13G and the Amendment jointly in accordance with the provisions of Rule 13d-1(k) of the Act. The filing of this Amendment should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of common stock, par value $0.0001 per share, of the issuer (the "Common Stock") reported herein.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is 2011 Bradford Hall Place, Charlotte, NC 28270.
    (c)Citizenship:

    AME is a North Carolina limited liability company. Ms. Friedman is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    171126204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The purpose of this Amendment is to amend and supplement the Schedule 13G in order to update the beneficial ownership information on the cover pages and in Item 4 in the Schedule 13G, including to indicate that each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock and to amend Item 5 of the Schedule 13G accordingly. This Amendment constitutes an exit filing for each of the Reporting Persons. The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Amendment and is incorporated herein by reference for each such Reporting Person. None of the Reporting Persons beneficially owns any shares of Common Stock. Ms. Friedman, as the manager of AME, has shared power to vote and/or dispose of any shares of Common Stock beneficially owned by AME. By reason of the provisions of Rule 13d-3 of the Act, Ms. Friedman may be deemed to beneficially own any shares of Common Stock beneficially owned by AME.
    (b)Percent of class:

    0 %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (A) AME: 0.00 (B) Ms. Friedman: 0.00

     (ii) Shared power to vote or to direct the vote:

    (A) AME: 0.00 (B) Ms. Friedman: 0.00

     (iii) Sole power to dispose or to direct the disposition of:

    (A) AME: 0.00 (B) Ms. Friedman: 0.00

     (iv) Shared power to dispose or to direct the disposition of:

    (A) AME: 0.00 (B) Ms. Friedman: 0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 1 filed with the Schedule 13G.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    AME Equities LLC
     
    Signature:/s/ Ruth Friedman
    Name/Title:Ruth Friedman, Manager of AME Equities LLC
    Date:08/13/2025
     
    Ruth Friedman
     
    Signature:/s/ Ruth Friedman
    Name/Title:Ruth Friedman
    Date:08/13/2025

    Comments accompanying signature:  LIST OF EXHIBITS Exhibit No. 1 - Joint Filing Agreement, dated March 1, 2024 (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on March 1, 2024).
    Get the next $PTHS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTHS

    DatePrice TargetRatingAnalyst
    9/2/2025$50.00Outperform
    Oppenheimer
    More analyst ratings

    $PTHS
    SEC Filings

    View All

    SEC Form 424B3 filed by Pelthos Therapeutics Inc.

    424B3 - Pelthos Therapeutics Inc. (0001919246) (Filer)

    9/29/25 4:21:09 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Pelthos Therapeutics Inc.

    EFFECT - Pelthos Therapeutics Inc. (0001919246) (Filer)

    9/25/25 12:15:11 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-3/A filed by Pelthos Therapeutics Inc.

    S-3/A - Pelthos Therapeutics Inc. (0001919246) (Filer)

    9/19/25 4:31:25 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

    DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference. Investor Conference Details: H.C. Wainwright 27th Annual Global Investment ConferenceLocation: Lotte New York Palace Hotel, New York CityConference Dates: September 8-10, 2025Presentation Date: September 10, 2025 at 10:30 A.M.

    9/8/25 8:30:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference

    DURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel, CFO, will participate in the Wells Fargo Healthcare Conference. Management's presentation will take place on Wednesday, September 3rd, 2025 at 1:30 p.m. E.T. For one-on-one meeting requests please contact your institutional sales representative. A webcast of the presentation will be available on the Events and Presentations pages of Pelthos' website at https://pelthos.com. Archived replays will be

    9/2/25 8:00:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

    Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient nee

    8/18/25 8:00:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Plesha Scott M.

    4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    7/23/25 9:17:40 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Plesha Scott M.

    3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    7/23/25 9:14:01 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Rangarao Sai

    4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

    7/21/25 8:26:43 PM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Pelthos Therapeutics Inc. with a new price target

    Oppenheimer initiated coverage of Pelthos Therapeutics Inc. with a rating of Outperform and set a new price target of $50.00

    9/2/25 8:39:24 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTHS
    Leadership Updates

    Live Leadership Updates

    View All

    Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

    Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient nee

    8/18/25 8:00:00 AM ET
    $PTHS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care